Company intelligence / Profile preview
Tosk, Inc.
Mountain View, California, United Statestosk.com ↗
- Ownership
- Private
- Employees
- ~14
- Development stage
- Commercial
01
Overview
TK-90 has completed Phase 2a clinical studies demonstrating safety and efficacy in head and neck cancer patients for preventing mucositis. Results show TK-90 can block virtually all mucositis caused by chemotherapy and radiation therapy. The company is planning a Phase 2b/3 registration study for TK-90 by the end of 2024[2][3].
- Therapeutic areas
- GastroenterologyPulmonologyCardiovascularNephrologyOncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
National Cancer Institute
Beyond the preview
Go deeper on Tosk, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tosk, Inc..